Background: Regulatory T cells (Tregs) suppress T-cell immune activation and human immunodeficiency virus type 1 (HIV-1) replication, but the role of Tregs in HIV-1 reservoir persistence is poorly defined. Methods: Tregs were depleted by denileukin diftitox in humanized mice with chronic HIV-1 infection. Viral replication in lineage cells was determined by p24 expression. Levels of HIV-1 RNA and DNA in human cells, as well as replication-competent-virus-producing cells, were measured to quantified viral replication and reservoirs. Results: Treg depletion resulted in a blip of HIV-1 replication in T cells but not in myeloid cells. The major activated reservoir cells were memory CD4+ T cells in vivo. Interestingly, the transient activation of viral replication led to HIV-1 reservoir reduction after viremia resuppression, as indicated by the quantity of HIV-1 DNA and replication-competent-virus-producing cells. Furthermore, we demonstrated that Tregs use cyclic adenosine monophosphate (cAMP)-dependent protein kinase A pathway to inhibit HIV-1 activation and replication in resting conventional T cells in vitro. Conclusion: Tregs suppress HIV-1 replication in T cells and contribute to HIV-1 reservoir persistence. cAMP produced in Tregs is involved in their suppression of viral gene activation and expression. Treg depletion combined with combination antiretroviral therapy provides a novel strategy for HIV-1 cure.
Background: Regulatory T cells (Tregs) suppress T-cell immune activation and human immunodeficiency virus type 1 (HIV-1) replication, but the role of Tregs in HIV-1 reservoir persistence is poorly defined. Methods: Tregs were depleted by denileukin diftitox in humanized mice with chronic HIV-1 infection. Viral replication in lineage cells was determined by p24 expression. Levels of HIV-1 RNA and DNA in human cells, as well as replication-competent-virus-producing cells, were measured to quantified viral replication and reservoirs. Results: Treg depletion resulted in a blip of HIV-1 replication in T cells but not in myeloid cells. The major activated reservoir cells were memory CD4+ T cells in vivo. Interestingly, the transient activation of viral replication led to HIV-1 reservoir reduction after viremia resuppression, as indicated by the quantity of HIV-1 DNA and replication-competent-virus-producing cells. Furthermore, we demonstrated that Tregs use cyclic adenosine monophosphate (cAMP)-dependent protein kinase A pathway to inhibit HIV-1 activation and replication in resting conventional T cells in vitro. Conclusion: Tregs suppress HIV-1 replication in T cells and contribute to HIV-1 reservoir persistence. cAMP produced in Tregs is involved in their suppression of viral gene activation and expression. Treg depletion combined with combination antiretroviral therapy provides a novel strategy for HIV-1 cure.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Susanna L Lamers; Rebecca Rose; Ekaterina Maidji; Melissa Agsalda-Garcia; David J Nolan; Gary B Fogel; Marco Salemi; Debra L Garcia; Paige Bracci; William Yong; Deborah Commins; Jonathan Said; Negar Khanlou; Charles H Hinkin; Miguel Valdes Sueiras; Glenn Mathisen; Suzanne Donovan; Bruce Shiramizu; Cheryl A Stoddart; Michael S McGrath; Elyse J Singer Journal: J Virol Date: 2016-09-29 Impact factor: 5.103
Authors: Maria E Moreno-Fernandez; Wildeman Zapata; Jason T Blackard; Genoveffa Franchini; Claire A Chougnet Journal: J Virol Date: 2009-10-14 Impact factor: 5.103
Authors: Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia Journal: J Virol Date: 2011-10-19 Impact factor: 5.103
Authors: Tobias Bopp; Christian Becker; Matthias Klein; Stefan Klein-Hessling; Alois Palmetshofer; Edgar Serfling; Valeska Heib; Marc Becker; Jan Kubach; Steffen Schmitt; Sabine Stoll; Hansjörg Schild; Martin S Staege; Michael Stassen; Helmut Jonuleit; Edgar Schmitt Journal: J Exp Med Date: 2007-05-14 Impact factor: 14.307
Authors: Jatin Machhi; Bhavesh D Kevadiya; Ijaz Khan Muhammad; Jonathan Herskovitz; Katherine E Olson; R Lee Mosley; Howard E Gendelman Journal: Mol Neurodegener Date: 2020-06-05 Impact factor: 14.195
Authors: Diogo G Caetano; Hury H S de Paula; Gonzalo Bello; Brenda Hoagland; Larissa M Villela; Beatriz Grinsztejn; Valdilea G Veloso; Mariza G Morgado; Monick L Guimarães; Fernanda H Côrtes Journal: PLoS One Date: 2020-02-05 Impact factor: 3.240